ARTICLE | Company News
Geron other research news
June 6, 1994 7:00 AM UTC
Geron (Menlo Park, Calif.) received a $75,000 Phase I SBIR from the National Cancer Institute to develop anti-cancer drugs that target telomerase, an enzyme responsible for the immortality of cancer c...